The PTEN and INK4A/ARF tumor suppressors maintain myelolymphoid homeostasis and cooperate to constrain histiocytic sarcoma development in humans

被引:57
作者
Carrasco, Daniel R.
Fenton, Tim
Sukhdeo, Kumar
Protopopova, Marina
Enos, Miriam
You, Mingjian J.
Divicio, Dolores
Nogueira, Cristina
Stommel, Jayne
Pinkus, Geraldine S.
Fletcher, Christopher
Hornick, Jason L.
Cavenee, Webster K.
Furnari, Frank B.
DePinho, Ronald A. [1 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA 02115 USA
[3] Univ Calif San Diego, Ludwig Inst Canc Res, Sch Med, La Jolla, CA 92093 USA
[4] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[5] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Appl Canc Sci,Belfer Fdn Inst Innovat Canc Sc, Boston, MA 02115 USA
关键词
D O I
10.1016/j.ccr.2006.03.028
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Histiocytic sarcoma (HS) is a rare malignant proliferation of histiocytes of uncertain molecular pathogenesis. Here, genetic analysis of coincident loss of Pten and Ink4a/Arf tumor suppressors in the mouse revealed a neoplastic phenotype dominated by a premalignant expansion of biphenotypic myelolymphoid cells followed by the development of HS. Pten protein loss occurred only in the histiocytic portion of tumors, suggesting a stepwise genetic inactivation in the generation of HS. Similarly, human HS showed genetic or epigenetic inactivation of PTEN, p16(INK4A), and p14(ARF), supporting the relevance of this genetically engineered mouse model of HS. These genetic and translational observations establish a cooperative role of Pten and Ink4a/Arf in the development of HS and provide mechanistic insights into the pathogenesis of human HS.
引用
收藏
页码:379 / 390
页数:12
相关论文
共 52 条
[1]  
BANKS PM, 2001, WHO CLASSIFICATION T, P189
[2]   Classification of acute leukemias [J].
Brunning, RD .
SEMINARS IN DIAGNOSTIC PATHOLOGY, 2003, 20 (03) :142-153
[3]   Methylation silencing and mutations of the p14ARF and p16INK4a genes in colon cancer [J].
Burri, N ;
Shaw, P ;
Bouzourene, H ;
Sordat, I ;
Sordat, B ;
Gillet, M ;
Schorderet, D ;
Bosman, FT ;
Chaubert, P .
LABORATORY INVESTIGATION, 2001, 81 (02) :217-229
[4]   New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway [J].
Cantley, LC ;
Neel, BG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4240-4245
[5]  
CLINE MJ, 1994, BLOOD, V84, P2840
[6]   Impaired Fas response and autoimmunity in Pten+/- mice [J].
Di Cristofano, A ;
Kotsi, P ;
Peng, YF ;
Cordon-Cardo, C ;
Elkon, KB ;
Pandolfi, PP .
SCIENCE, 1999, 285 (5436) :2122-2125
[7]  
Eischen CM, 2002, CANCER RES, V62, P2184
[8]  
Esteller M, 2001, CANCER RES, V61, P2816
[9]  
HAUPT Y, 1992, ONCOGENE, V7, P981
[10]   Mechanisms of disease: Gene silencing in cancer in association with promoter hypermethylation [J].
Herman, JG ;
Baylin, SB .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :2042-2054